NEWS AND INSIGHTS

Take Surge Pricing to the Limit. Then Go Further.

News & Insights

The New York Times’ John Schwartz asks Eric Dezenhall about why Martin Shkreli the Turing Pharmaceutical executive who raised its drug Daraprim price to $750 a pill from $13.50 was vilified so quickly. Read the article for Eric’s simple answer.

From The New York Times
Eric Dezenhall, reputation management, Shkreli, surge pricing

Back to News and Insights